Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cardiol Therapeutics Inc (CRDL.TO)

Cardiol Therapeutics Inc (CRDL.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 211,696
  • Shares Outstanding, K 79,585
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,128 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.00
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 13.78
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.44
  • Most Recent Earnings $-0.10 on 08/12/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Drug Specialty & Generic

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.45 +6.94%
on 10/31/24
2.94 -10.88%
on 11/07/24
+0.01 (+0.38%)
since 10/11/24
3-Month
2.14 +22.43%
on 10/09/24
3.57 -26.61%
on 09/13/24
-0.09 (-3.32%)
since 08/14/24
52-Week
1.07 +144.86%
on 12/22/23
4.26 -38.50%
on 06/12/24
+1.43 (+120.17%)
since 11/14/23

Most Recent Stories

More News
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase...

CRDL.TO : 2.62 (-1.50%)
CRDL : 1.8600 (-2.62%)
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL.TO : 2.62 (-1.50%)
CRDL : 1.8600 (-2.62%)
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Oakville, Ontario--(Newsfile Corp. - October 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL.TO : 2.62 (-1.50%)
CRDL : 1.8600 (-2.62%)
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Oakville, Ontario--(Newsfile Corp. - October 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL.TO : 2.62 (-1.50%)
CRDL : 1.8600 (-2.62%)
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL.TO : 2.62 (-1.50%)
CRDL : 1.8600 (-2.62%)
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Toronto, Ontario--(Newsfile Corp. - September 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL.TO : 2.62 (-1.50%)
CRDL : 1.8600 (-2.62%)
Stocks in play: Cardiol Therapeutics Inc

Announced the data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRxâ„¢ ...

CRDL.TO : 2.62 (-1.50%)
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024Toronto, Ontario--(Newsfile Corp. - September...

CRDL : 1.8600 (-2.62%)
CRDL.TO : 2.62 (-1.50%)
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and...

CRDL : 1.8600 (-2.62%)
CRDL.TO : 2.62 (-1.50%)
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and...

CRDL : 1.8600 (-2.62%)
CRDL.TO : 2.62 (-1.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol...

See More

Key Turning Points

3rd Resistance Point 2.86
2nd Resistance Point 2.79
1st Resistance Point 2.71
Last Price 2.62
1st Support Level 2.56
2nd Support Level 2.49
3rd Support Level 2.41

See More

52-Week High 4.26
Fibonacci 61.8% 3.04
Fibonacci 50% 2.67
Last Price 2.62
Fibonacci 38.2% 2.29
52-Week Low 1.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar